EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017

  • ID: 4091115
  • Report
  • February 2017
  • 135 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Bionomics Ltd
  • Chronos Therapeutics Ltd
  • Eli Lilly and Company
  • NeuroNascent Inc
  • Otsuka Holdings Co Ltd
  • MORE
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 17 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Bionomics Ltd
  • Chronos Therapeutics Ltd
  • Eli Lilly and Company
  • NeuroNascent Inc
  • Otsuka Holdings Co Ltd
  • MORE
Introduction

Post-Traumatic Stress Disorder (PTSD) - Overview

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Amorsa Therapeutics Inc

Azevan Pharmaceuticals Inc

Bionomics Ltd

Catalyst Pharmaceuticals Inc

Cerecor Inc

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Eli Lilly and Company

Embera NeuroTherapeutics Inc

Intra-Cellular Therapies Inc

INVENT Pharmaceuticals Inc

Marinus Pharmaceuticals Inc

Neuralstem Inc

NeuroNascent Inc

Omeros Corp

Otsuka Holdings Co Ltd

Pragma Therapeutics SAS

Synchroneuron Inc

Tonix Pharmaceuticals Holding Corp

TRImaran Pharma Inc

Post-Traumatic Stress Disorder (PTSD) - Drug Profiles

(metyrapone + oxazepam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acamprosate calcium SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71743 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-3506 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brexpiprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CERC-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPP-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganaxolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-87201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDAC-0001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumateperone tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

midomafetamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

modafinil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NNI-351 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSI-189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGT-117 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rycal - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize EP1 for Post-Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-246 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Target NPSR for Anxiety Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tianeptine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZL-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects

Post-Traumatic Stress Disorder (PTSD) - Discontinued Products

Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones

Featured News & Press Releases

Feb 09, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO & Investor Conference

Jan 24, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13

Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-601 at 9th Annual Biotech Showcase Conference

Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-102 at 9th Annual Biotech Showcase Conference

Jan 05, 2017: Marinus Provides Business Outlook for

Jan 03, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference

Dec 19, 2016: Tonix Pharmaceuticals' PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA

Dec 08, 2016: Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder

Dec 02, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Nov 10, 2016: Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD

Nov 07, 2016: Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting

Nov 02, 2016: Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe International Partnering Conference

Nov 01, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress

Oct 27, 2016: Tonix Pharmaceuticals to Present Clinical Data at CNS Summit

Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Cerecor Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by INVENT Pharmaceuticals Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1

Post-Traumatic Stress Disorder (PTSD) - Pipeline by TRImaran Pharma Inc, H1

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2017 (Contd..1), H1

Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1

List of Figures:

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc
  • Azevan Pharmaceuticals Inc
  • Bionomics Ltd
  • Catalyst Pharmaceuticals Inc
  • Cerecor Inc
  • Chronos Therapeutics Ltd
  • Corcept Therapeutics Inc
  • Eli Lilly and Company
  • Embera NeuroTherapeutics Inc
  • Intra-Cellular Therapies Inc
  • INVENT Pharmaceuticals Inc
  • Marinus Pharmaceuticals Inc
  • Neuralstem Inc
  • NeuroNascent Inc
  • Omeros Corp
  • Otsuka Holdings Co Ltd
  • Pragma Therapeutics SAS
  • Synchroneuron Inc
  • Tonix Pharmaceuticals Holding Corp
  • TRImaran Pharma Inc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll